Literature DB >> 10229228

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.

C J Pitcher1, C Quittner, D M Peterson, M Connors, R A Koup, V C Maino, L J Picker.   

Abstract

The role of HIV-1-specific CD4+ T-cell responses in controlling HIV-1 infection remains unclear. Previous work has suggested that such cells are eliminated in the early stages of infection in most subjects, and thus cannot substantially contribute to host defense against HIV-1. Here, using flow cytometric detection of antigen-induced intracellular cytokines, we show that significant frequencies of gag specific, T-helper-1 CD4+ memory T cells are detectable in most subjects with active/progressive HIV-1 infection (median frequency, 0.12% of memory subset; range, 0-0.66%). Median frequencies of these cells were considerably higher in nonprogressive HIV-1 disease (0.40%), but there was substantial overlap between the two groups (range of nonprogressors, 0.10-1.7%). Continuous HIV-1 suppression with anti-retroviral therapy was associated with a time-dependent reduction in median frequencies of gag-specific CD4+ memory T cells: 0.08% in subjects treated for 4-24 weeks, and 0.03% in subjects treated for 47-112 weeks. Thus, functional HIV-1-specific CD4+ T cells are commonly available for support of anti-HIV-1 effector responses in active disease, but their decline with anti-retroviral therapy indicates that immunologic participation in long-term HIV-1 control will probably require effective vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229228     DOI: 10.1038/8400

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  238 in total

1.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 3.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

4.  MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.

Authors:  J N Blankson; R F Siliciano
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 5.  Immunofluorescence analysis of T-cell responses in health and disease.

Authors:  H T Maecker; V C Maino; L J Picker
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

6.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

7.  Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta.

Authors:  R Kamin-Lewis; S F Abdelwahab; C Trang; A Baker; A L DeVico; R C Gallo; G K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

8.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

9.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

10.  Expansion of activated human naïve T-cells precedes effector function.

Authors:  J M Brenchley; D C Douek; D R Ambrozak; M Chatterji; M R Betts; L S Davis; R A Koup
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.